New drug tested to shrink tumors before prostate removal

NCT ID NCT06613100

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new drug called xaluritamig, given to men before they have surgery to remove their prostate. The main goals are to see if the drug is safe and if it's practical to perform surgery after patients receive it. Researchers will enroll about 40 men with newly diagnosed, non-metastatic prostate cancer that is considered intermediate or high risk.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109-1023, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
Universitaetsklinikum Essen
RECRUITING

Essen, 45147, Germany
Universitaetsklinikum Hamburg Eppendorf
RECRUITING

Hamburg, 20246, Germany
University of California San Francisco
RECRUITING

San Francisco, California, 94143, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER